Clinical Trial Update: Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating C402-CD19-CAR for relapsed or refractory B-cell lymphomas is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma Grade 3b
• High-grade B-cell Lymphoma Not Otherwise Specified
• High-grade B-cell Lymphoma with Myc and Bcl2 and or Bcl6 Rearrangements
• Mediastinal Large B-cell Lymphoma

Drugs mentioned

• C402-CD19-CAR

Snippet

Sponsor: Shanghai Exuma Biotechnology Ltd. | Conditions: Diffuse Large B-cell-lymphoma, DLBCL, Nos Genetic Subtypes | Phase 1 | Status: RECRUITING